Michael Choi is an Oncology physician. ClinicalTrials.gov lists 11 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 W Arbor Dr
San Diego, CA 921039000
Telephone
858-822-6100Provider last certified this registry record 12 Nov 2025.
Clinical trials
- Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients
Sponsor: University of California, San Diego
- Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
Sponsor: Michael Choi
- A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
Sponsor: Oncternal Therapeutics, Inc
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Rigel Pharmaceuticals, Inc.Program year20252 payments
- AstraZeneca Pharmaceuticals LPProgram year20252 payments
- Medexus Pharma, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
74.7%Kinase inhibitor56.4%Calquence33%Brukinsa33%Imbruvica28%Jaypirca4%Jakafi2%Part D<11 patientsBCL-2 Inhibitor12.5%Venclexta100%Part D≥17 patients+ 1 more class in this area
Anti-infectives
8.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor4.5%Valacyclovir100%Part D≥13 patientsShort-acting sulfonamides2.9%Sulfamethoxazole-Trimethoprim100%Part D<11 patients+ 1 more class in this area
Dermatology
7.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor7.1%Acyclovir100%Part D≥20 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”